S&P 500   4,609.10 (+0.10%)
DOW   36,356.00 (+0.30%)
QQQ   394.51 (+0.60%)
AAPL   192.26 (-1.76%)
MSFT   370.38 (-1.03%)
META   322.11 (-3.20%)
GOOGL   132.68 (-1.71%)
AMZN   145.00 (-1.64%)
TSLA   241.42 (-0.99%)
NVDA   463.64 (-2.40%)
NIO   7.45 (+0.95%)
BABA   71.43 (-0.98%)
AMD   134.10 (+4.02%)
T   16.63 (-1.71%)
F   11.08 (+0.64%)
MU   77.77 (+3.75%)
CGC   0.82 (+2.43%)
GE   120.49 (-0.08%)
DIS   92.70 (-0.13%)
AMC   6.81 (-1.73%)
PFE   28.54 (-0.83%)
PYPL   59.54 (+1.02%)
XOM   99.17 (-0.38%)
S&P 500   4,609.10 (+0.10%)
DOW   36,356.00 (+0.30%)
QQQ   394.51 (+0.60%)
AAPL   192.26 (-1.76%)
MSFT   370.38 (-1.03%)
META   322.11 (-3.20%)
GOOGL   132.68 (-1.71%)
AMZN   145.00 (-1.64%)
TSLA   241.42 (-0.99%)
NVDA   463.64 (-2.40%)
NIO   7.45 (+0.95%)
BABA   71.43 (-0.98%)
AMD   134.10 (+4.02%)
T   16.63 (-1.71%)
F   11.08 (+0.64%)
MU   77.77 (+3.75%)
CGC   0.82 (+2.43%)
GE   120.49 (-0.08%)
DIS   92.70 (-0.13%)
AMC   6.81 (-1.73%)
PFE   28.54 (-0.83%)
PYPL   59.54 (+1.02%)
XOM   99.17 (-0.38%)
S&P 500   4,609.10 (+0.10%)
DOW   36,356.00 (+0.30%)
QQQ   394.51 (+0.60%)
AAPL   192.26 (-1.76%)
MSFT   370.38 (-1.03%)
META   322.11 (-3.20%)
GOOGL   132.68 (-1.71%)
AMZN   145.00 (-1.64%)
TSLA   241.42 (-0.99%)
NVDA   463.64 (-2.40%)
NIO   7.45 (+0.95%)
BABA   71.43 (-0.98%)
AMD   134.10 (+4.02%)
T   16.63 (-1.71%)
F   11.08 (+0.64%)
MU   77.77 (+3.75%)
CGC   0.82 (+2.43%)
GE   120.49 (-0.08%)
DIS   92.70 (-0.13%)
AMC   6.81 (-1.73%)
PFE   28.54 (-0.83%)
PYPL   59.54 (+1.02%)
XOM   99.17 (-0.38%)
S&P 500   4,609.10 (+0.10%)
DOW   36,356.00 (+0.30%)
QQQ   394.51 (+0.60%)
AAPL   192.26 (-1.76%)
MSFT   370.38 (-1.03%)
META   322.11 (-3.20%)
GOOGL   132.68 (-1.71%)
AMZN   145.00 (-1.64%)
TSLA   241.42 (-0.99%)
NVDA   463.64 (-2.40%)
NIO   7.45 (+0.95%)
BABA   71.43 (-0.98%)
AMD   134.10 (+4.02%)
T   16.63 (-1.71%)
F   11.08 (+0.64%)
MU   77.77 (+3.75%)
CGC   0.82 (+2.43%)
GE   120.49 (-0.08%)
DIS   92.70 (-0.13%)
AMC   6.81 (-1.73%)
PFE   28.54 (-0.83%)
PYPL   59.54 (+1.02%)
XOM   99.17 (-0.38%)

Atreca (BCEL) Competitors

$0.22
-0.02 (-8.30%)
(As of 10:56 AM ET)
Compare
Today's Range
$0.22
$0.24
50-Day Range
$0.20
$0.38
52-Week Range
$0.19
$2.05
Volume
316,636 shs
Average Volume
670,440 shs
Market Capitalization
$8.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.75

BCEL vs. CANF, ALRN, TRVN, NTBL, IMNN, GTBP, GRTX, SHPH, BNTC, and EVLO

Should you be buying Atreca stock or one of its competitors? The main competitors of Atreca include Can-Fite BioPharma (CANF), Aileron Therapeutics (ALRN), Trevena (TRVN), Notable Labs (NTBL), Imunon (IMNN), GT Biopharma (GTBP), Galera Therapeutics (GRTX), Shuttle Pharmaceuticals (SHPH), Benitec Biopharma (BNTC), and Evelo Biosciences (EVLO). These companies are all part of the "medical" sector.

Atreca vs.

Atreca (NASDAQ:BCEL) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Atreca has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.

Can-Fite BioPharma has higher revenue and earnings than Atreca. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtrecaN/AN/A-$97.16M-$2.50-0.09
Can-Fite BioPharma$785K9.74-$10.17M-$2.59-0.83

Atreca has a net margin of 0.00% compared to Can-Fite BioPharma's net margin of -1,146.62%. Can-Fite BioPharma's return on equity of -143.59% beat Atreca's return on equity.

Company Net Margins Return on Equity Return on Assets
AtrecaN/A -157.90% -71.39%
Can-Fite BioPharma -1,146.62%-143.59%-83.78%

Atreca presently has a consensus target price of $10.75, suggesting a potential upside of 4,764.25%. Can-Fite BioPharma has a consensus target price of $15.00, suggesting a potential upside of 594.44%. Given Atreca's higher probable upside, equities analysts plainly believe Atreca is more favorable than Can-Fite BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atreca
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Atreca received 94 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 67.86% of users gave Atreca an outperform vote while only 4.35% of users gave Can-Fite BioPharma an outperform vote.

CompanyUnderperformOutperform
AtrecaOutperform Votes
95
67.86%
Underperform Votes
45
32.14%
Can-Fite BioPharmaOutperform Votes
1
4.35%
Underperform Votes
22
95.65%

34.9% of Atreca shares are held by institutional investors. Comparatively, 1.5% of Can-Fite BioPharma shares are held by institutional investors. 11.3% of Atreca shares are held by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Can-Fite BioPharma had 3 more articles in the media than Atreca. MarketBeat recorded 3 mentions for Can-Fite BioPharma and 0 mentions for Atreca. Can-Fite BioPharma's average media sentiment score of 0.52 beat Atreca's score of 0.45 indicating that Can-Fite BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
Atreca Neutral
Can-Fite BioPharma Positive

Summary

Atreca beats Can-Fite BioPharma on 9 of the 16 factors compared between the two stocks.


Get Atreca News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCEL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCEL vs. The Competition

MetricAtrecaBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$8.76M$292.63M$4.29B$6.69B
Dividend YieldN/A3.49%5.48%4.55%
P/E Ratio-0.09264.07120.9914.28
Price / SalesN/A18,386.143,009.60398.77
Price / CashN/A11.2078.97128.32
Price / Book0.114.124.054.67
Net Income-$97.16M-$37.64M$119.62M$175.93M
7 Day Performance-5.35%-0.93%112.33%4.99%
1 Month Performance-7.92%3.84%125.74%15.52%
1 Year Performance-75.71%43.64%129.30%8.07%

Atreca Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CANF
Can-Fite BioPharma
1.689 of 5 stars
$2.40
+0.8%
$15.00
+525.0%
N/A$8.50M$810,000.00-0.788Analyst Report
News Coverage
Gap Down
ALRN
Aileron Therapeutics
2.0864 of 5 stars
$1.90
+4.4%
N/A-8.4%$8.63MN/A0.006Gap Down
TRVN
Trevena
2.0735 of 5 stars
$0.57
+1.8%
$5.50
+856.7%
-72.7%$8.72M$570,000.00-0.2135Analyst Report
Gap Up
NTBL
Notable Labs
1.6907 of 5 stars
$3.94
-1.3%
$13.00
+229.9%
N/A$8.75M$660,000.00-1.0913
IMNN
Imunon
2.2458 of 5 stars
$0.94
flat
$12.00
+1,176.6%
-40.4%$8.84M$500,000.00-0.2931Positive News
Gap Up
GTBP
GT Biopharma
1.9177 of 5 stars
$0.22
-4.4%
$3.50
+1,527.9%
-85.3%$8.91MN/A-0.722Gap Up
GRTX
Galera Therapeutics
1.8071 of 5 stars
$0.15
flat
$7.75
+5,244.8%
-92.2%$7.84MN/A-0.0831Positive News
SHPH
Shuttle Pharmaceuticals
0 of 5 stars
$0.49
-2.0%
N/A-81.8%$7.81MN/A0.007Positive News
BNTC
Benitec Biopharma
1.784 of 5 stars
$3.05
-4.1%
$6.50
+113.1%
+14.3%$7.78M$80,000.00-1.8818
EVLO
Evelo Biosciences
1.5908 of 5 stars
$0.41
-2.4%
$70.00
+16,973.2%
-99.0%$7.76MN/A-0.0366Gap Down

Related Companies and Tools

This page (NASDAQ:BCEL) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -